REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.16
+1.51 (17.46%)
Mar 9, 2026, 2:40 PM EDT - Market open
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$459,410
Profits / Employee
-$522,582
Market Cap
524.39M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| 4D Molecular Therapeutics | 227 |
| Entrada Therapeutics | 152 |
| Century Therapeutics | 150 |
| Kyverna Therapeutics | 129 |
| Lineage Cell Therapeutics | 77 |
| Assembly Biosciences | 73 |
| Altimmune | 59 |
RGNX News
- 3 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 3 days ago - REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - PRNewsWire
- 4 days ago - REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - PRNewsWire
- 5 days ago - REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 6 days ago - REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses - PRNewsWire
- 7 days ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 12 days ago - REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - PRNewsWire